title: [Effective clinical use of cyclophosphamide in hematological malignancies].
abstract: Cyclophosphamide (CPA) is the most widely used alkylating agent in the treatment of hematological malignancies. We review current clinical potential of high-dose CPA administration in this field. The efficacy of dose intensification of CPA in CHOP regimen for patients with aggressive lymphoma is being investigated in some clinical trials. High-dose CPA administration and G-CSF infusion effectively mobilize high levels of peripheral blood stem cell suitable for autografting. High-dose regimens of CPA alone or in combination with other agents also have been used to treat various hematological malignancies in conjunction with stem cell transplantation (SCT). A variety of adverse effects have been observed with the high-dose CPA used in preparative regimens for SCT. Hemorrhagic cystitis and cardiac toxicity are common and dose-limiting toxic effect of high-dose CPA administration.
authors.affiliation: Dept. of Internal Medicine, Fujita Health University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Miyazaki
authors.forename: M
authors.initials: M
authors.lastname: Hirano
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone